Based on ratings from 0 stock analysts, the GRAIL, Inc. stock price is expected to decrease by 100% in 12 months. This is calculated by using the average 12-month stock price forecast for GRAIL, Inc.. The lowest target is $ and the highest is $. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedGRAL 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect GRAIL, Inc. to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on GRAL. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of GRAL.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Subbu Nambi Guggenheim | Neutral | Initiates | Oct 17, 2024 |
When did it IPO
2024
Staff Count
1,360
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. Robert P. Ragusa
Market Cap
$449.6M
In 2023, GRAL generated $93.1M in revenue, which was a increase of 67.61% from the previous year. This can be seen as a signal that GRAL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - GRAIL, Inc. reported a 52% YoY revenue increase to $25.4 million for Q3 2024, with over 250,000 Galleri tests sold. The company has a cash balance of $853.6 million, funding operations through 2028.
Why It Matters - Galleri's 52% revenue growth and significant test sales indicate strong market demand. A cash balance of $853.6 million ensures financial stability, enhancing growth potential and investor confidence.
Summary - GRAIL, Inc. (Nasdaq: GRAL) will present at the Canaccord Genuity MedTech Forum in New York on Nov. 21 at 11:00 a.m., focusing on early cancer detection.
Why It Matters - GRAIL's presentation at a prominent healthcare forum could signal its growth potential and attract investor interest, influencing stock performance and market perception.
Summary - GRAIL, Inc. (Nasdaq: GRAL) will release its Q3 2024 financial results on Nov. 12, 2024, after market close.
Why It Matters - GRAIL's Q3 2024 financial results announcement could impact stock performance, reflecting its operational progress and potential market reception of its cancer detection technology.
Summary - GRAIL, Inc. has appointed Sarah Krevans to its Board of Directors, effective immediately, as part of its focus on early cancer detection.
Why It Matters - Sarah Krevans joining GRAIL's Board may signal strategic growth and enhanced leadership, potentially boosting investor confidence and impacting stock performance positively.
Summary - GRAIL, Inc. announced early results from the REFLECTION study, evaluating the Galleriยฎ multi-cancer early detection test in diverse clinical settings, focusing on real-world effectiveness.
Why It Matters - Positive results from the REFLECTION study could boost GRAIL's stock value, indicating strong demand for the Galleriยฎ test and enhancing its market position in early cancer detection.
Summary - Insider buying has significantly decreased ahead of the third-quarter earnings reporting season, indicating potential caution among executives.
Why It Matters - Insider buying trends can indicate company confidence; a slowdown may signal caution or uncertainty about forthcoming earnings, potentially affecting stock performance.